122 results
424B5
VBIVQ
VBI Vaccines Inc
15 May 24
Prospectus supplement for primary offering
4:16pm
research and development grants. However, our revenues have not been significant to date. Our long-term success and ability to continue as a going concern … adjusted tax basis in its common shares.
This capital gain or loss will be long-term capital gain or loss if the U.S. Holder’s holding period in its
424B5
VBIVQ
VBI Vaccines Inc
11 Apr 24
Prospectus supplement for primary offering
9:06am
agreements, and certain governmental research and development grants. However, our revenues have not been significant to date. Our long-term success … , as amended, as a current liability rather than a long-term liability due to the failure to meet the minimum Net Revenue covenant for the measurement
8-K
EX-99.1
pok6g0bm
2 Apr 24
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
8:00am
8-K
EX-99.1
8n2nqfpgl yl
14 Feb 24
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
8:34am
8-K
EX-99.1
yjnyhlw9k149l3yj5hib
14 Nov 23
VBI Vaccines Reports Third Quarter 2023 Financial Results
4:07pm
424B5
g2qg0zg
7 Jul 23
Prospectus supplement for primary offering
5:25pm
424B5
bs563
7 Jul 23
Prospectus supplement for primary offering
5:20pm
8-K
EX-1.1
yj1 zrofn
6 Jul 23
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
6:47pm
424B5
80w8ordfdhuvbb27r4
5 Jul 23
Prospectus supplement for primary offering
4:31pm
8-K
EX-99.1
an958f6e 9trhqgjj8
5 Jul 23
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-99.1
wl17vhapsksli
6 Dec 22
Entry into a Material Definitive Agreement
9:25am